This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
1 Population cohorts included adults ages 65 or older enrolled in Medicare and adults ages 19 to 64 years enrolled in Medicaid and deemed eligible for pneumococcal vaccination based on Advisory Committee on Immunization Practices recommendations. 1 Medicare enrollees were examined first.
Author(s): Alexandra Gerlach, Associate Editor , Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
Animals can be inaccurate testing models for human treatments, especially for disease states involving a human immune response, such as in cancer. 4 Testing also causes stress on the animals, leading to increased immune or biological responses and confounding disease data outcomes.
Pharmacist-led services, such as medication counseling, medication therapy management, comprehensive medication reviews, and general medical advice and recommendations, are also limited for patients living in a pharmacy desert.
Reduced immunity from COVID-19 precautions and low vaccination rates, especially among children and vulnerable groups, worsened the influenza season's impact. Systemic inequities, misinformation, and geographic disparities hindered vaccination efforts, with significant coverage gaps among racial and rural populations.
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Wick, MBA, RPh, FASCP, is the director of the Office of Pharmacy Professional Development at the University of Connecticut in Storrs.
Within the pharmacy, the average appointment time for contraception prescribing is just 20 minutes, and Meredith highlighted the importance of involving pharmacytechnicians to streamline the workflow. Waiting for an appointment with an OB-GYN can take weeks to months.
As health care rapidly changes, the role of pharmacists and pharmacytechnicians will have to evolve alongside it, said Donald Klepser, PhD, MBA, professor and interim dean at the University of Nebraska Medical Center.
Klein, MD, FRCP (C), FACC, FAHA, FASE, FESC, director at Pericardial Disease Center and professor of medicine, and Sean Krohn, PharmD, CSP, MSCS, lead clinical pharmacist, specialtypharmacy, discussed a complex case of severe pericarditis in an elderly patient who could not tolerate traditional treatments like NSAIDs or colchicine.
The study aimed to evaluate both safety and preliminary efficacy outcomes, with a specific focus on hematologic toxicity, pharmacokinetics, and immune system effects. Patients were trained to self-administer their infusion at home or attend clinic visits 3 times weekly.
link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
Jansen, PharmD Candidate , Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.
As this market surges toward unprecedented growth over the next decade, specialtypharmacies are increasingly turning to automation to meet demand and manage costs. Specialtypharmacies that prioritize efficiency over empathy risk missing what matters most: Meaningful connection during a critical moment in care.
Avatrombopag (Doptelet; Sobi) has been approved by the FDA for the treatment of pediatric patients aged 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. The decision is based on clinically meaningful data from the AVA-PED-301 study (NCT04516967).
This hesitancy can lead to delayed vaccination or outright refusal, directly impacting population-level immunity and increasing the risk of widespread influenza outbreaks and associated complications. 5,6 And pharmacists and pharmacytechnicians are perfectly suited to offer guidance and sound information on vaccination’s benefits.
Receiving CAR T therapy can take several weeks, and though very effective against difficult-to-treat cancers, it can sometimes cause life-threatening adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
SHOW MORE Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake. Pediatric vaccination laws vary, but pharmacists play a crucial role in educating families about vaccines like MMR, Tdap, and HPV. Before autumn approaches, start thinking about respiratory vaccines.
This single-center, retrospective, observational study included data from electronic health records and specialtypharmacies from January 1, 2023, to June 1, 2024, with specialtypharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period.
The session, which was entitled “Decoding the Logic: An Overview of Biologics and Biosimilars,” described clinical applications and economic impacts associated with biologics and biosimilars over the last 10 to 15 years, as well as outlined what skills effectively contribute to their management and understanding.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content